After having changed the treatment of heart failure with reduced ejection fraction: what are the latest evidences with sacubitril valsartan?
Edgardo Kaplinsky
摘要：1 Introduction
Sacubitril/valsartan (SV) is a first in class dual action molecule of the neprilysin (NEP) inhibitor prodrug sacubitril (AHU377) and the angiotensin Ⅱ receptor (Ang-Ⅱ) type Ⅰ antagonist valsartan.[1] It is the first angiotensin receptor-neprilysin inhibitor (ARNI) whose pharmacodynamic effects are consistent with a simultaneous stimulation of the natriuretic peptides system (via NEP inhibition) and the blockade of the renin-angiotensin-aldosterone system (valsartan effect) that finally results in systemic vasodilation,increased diuresis and natriuresis,reduction of plasmatic volume and diminution ofperioheral vascular resistance.
机标关键词：
论文发表日期：2019-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：5( 151-155 )
英文信息